TRZ — Peptide Protocol Wiki reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
Tirzepatide (Mounjaro/Zepbound): Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides? Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Tirzepatide 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Tirzepatide Weight Loss & Metabolism Anti-Obesity approved Tirzepatide Also known as: LY3298176, Mounjaro, Zepbound Compare with 13 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated January 29, 2026 Citations Verified TL;DR Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. FDA-approved as Mounjaro (2022) for type 2 diabetes and Zepbound (2023) for chronic weight management, tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid moiety that enables once-weekly dosing.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (6) · phenotypes (0)
evidence_reference, safety_reference, dosing_reference, contraindication_reference, mechanism
Findings (74) · awaiting review (55)
dosing · pending
Covers EXSCEL cardiovascular trial, Byetta/Bydureon dosing, and neuroprotection research.
dosing · pending
Lower doses of 5 mg and 10 mg produced 15% and 19.5% weight loss respectively.
regulatory · pending
Is tirzepatide FDA approved?
safety · pending
Tirzepatide (Mounjaro/Zepbound): Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?
regulatory · pending
Weight Loss & Metabolism Anti-Obesity Liraglutide Liraglutide: FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management.
dosing · pending
Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Tirzepatide 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Tirzepatide Weight Loss & Metabolism Anti-Obesity approved Tirzepatide Also known as: LY3298176, Mounjaro, Zepbound Compare with 13 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated January 29, 2026 Citations Verified TL;DR Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly.
dosing · pending
FDA-approved as Mounjaro (2022) for type 2 diabetes and Zepbound (2023) for chronic weight management, tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid moiety that enables once-weekly dosing.
dosing · pending
In the SURMOUNT-1 trial, participants achieved up to 22.5% mean body weight reduction at the highest dose.
regulatory · pending
Browse all metabolic peptides → Table of Contents 📌 TL;DR • FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound) • Dual GIP/GLP-1 receptor agonist with novel mechanism of action • Demonstrated up to 22.5% body weig
dosing · pending
ht reduction in clinical trials • Once-weekly subcutaneous injection for improved adherence • Significant HbA1c reduction (up to 2.58% in SURPASS trials) Community-Reported Side Effects Anecdotal ?
regulatory · pending
Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023).
dosing · pending
US Domestic View all 29 vendors → Explore Further Calculate Tirzepatide doses Pre-filled reconstitution and dose math for Tirzepatide New to peptides?
dosing · pending
📋 Protocol Quick-Reference Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) 💉 Dosing Amount 2.5 mg starting dose, escalating to 5-15 mg maintenance Frequency Once weekly Duration Ongoing (chronic therapy) Step-wise Titration 💊 Administration Route SC Schedule Once weekly Timing Same day each week, any time of day, without regard to meals ✓ Rotate injection sites 📅 Cycle Duration Ongoing (chronic therapy) Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Store refrigerated at 2-8 degrees C (36-46 degrees F) in the original carton to protect from light.
safety · pending
⚗️ Suggested Bloodwork ( 6 tests) HbA1c and fasting glucose When: Baseline Why: Baseline glycemic control Lipid panel When: Baseline Why: Baseline cardiovascular markers CMP with liver enzymes When: Baseline Why: Liver and kidney function Thyroid panel (TSH, free T4) When: Baseline Why: GLP-1 agonist class MTC warning Amylase and lipase When: Baseline Wh
dosing · pending
Covers LEADER cardiovascular trial, SCALE weight loss data, and Victoza/Saxenda dosing.
contraindication · pending
y: Baseline pancreatic function HbA1c When: 12 weeks Why: Monitor glycemic improvement (1.87-2.58% reduction expected) 💡 Key Considerations → Missed dose within 4 days: take ASAP → Store refrigerated; 21 days at room temp (max 30C) if needed → Contraindication: Avoid with personal/family history of medullary thyroid carcinoma or MEN2 syndrome; contraindicated in pregnancy Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.
outcome · pending
Restore access No thanks, continue reading Related Reading Peptide Semaglutide GLP-1 receptor agonist Peptide Retatrutide triple-agonist metabolic peptide Peptide Survodutide dual glucagon/GLP-1 agonist How Tirzepatide works at the cellular level Overview of Tirzepatide benefits and applications Scientific Details Molecular Formula C225H348N48O68 Molecular Weight 4813.45 Da CAS Number 2023788-19-2 Sequence Tyr(Aib)EGTFTSDVSSYLEGQAAKEFIAWLVKGR(C20 fatty diacid via Lys20-linker)-NH2 What is Tirzepatide?
mechanism · pending
# Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
dosing · pending
Developed by Eli Lilly, it is a 39-amino-acid synthetic peptide with a C20 fatty diacid side chain attached via a linker at lysine-20, enabling binding to albumin for once-weekly dosing p
regulatory · pending
Tirzepatide received FDA approval as Mounjaro in May 2022 for type 2 diabetes mellitus and as Zepbound in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
mechanism · pending
Mechanism of Action # Tirzepatide's dual agonism represents a novel approach to metabolic disease.
mechanism · pending
The peptide activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) with an imbalanced potency profile, showing approximately 5-fold greater potency at GIPR relative to native GIP, while having about 0.2-fold the potency of native GLP-1 at GLP-1R.
regulatory · pending
Learn the basics of peptide science and research Related Peptides View all peptides → Weight Loss & Metabolism Hormonal Health Exenatide Exenatide: the first GLP-1 receptor agonist ever approved, derived from Gila monster venom.
outcome · pending
Dual Incretin Signaling # GLP-1R activation : Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling GIPR activation : Potentiates insulin secretion, may improve lipid metabolism and fat distribution, enhances central appetite regulation Synergistic effects : The combination produces greater glycemic and weight effects than either pathway alone Pharmacokinetics # The C20 fatty diacid modification enables albumin binding, yielding a half-life of approximately 5 days and supporting once-weekly administration.
dosing · pending
Key findings include HbA1c reductions of 1.87-2.07% in treatment-naive T2D (SURPASS-1; Rosenstock J et al., Lancet 2021; PMID 34186022) 2 and body weight reductions of 15.0-20.9% across dose levels in obesity without diabetes (SURMOUNT-1; Jastreboff AM et al., NEJM 2022; PMID 35658024) 1 .
contraindication · pending
Important Considerations # Prescription medication requiring medical supervision Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 Most common adverse events are gastrointestinal (nausea, diarrhea, vomiting) Dose escalation schedule important to minimize GI side effects Key Research Findings # Efficacy and Safety of the Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial , published in The Lancet (Rosenstock J et al., 2021; PMID: 34186022): The study showed HbA1c reduction of 1.87% , 1.89% , and 2.07% vs 0.04% placebo The study showed body weight reduction of 7.0-9.5 kg across dose groups The study showed up to 52% of patients achieved HbA1c below 5.7% at the 15 mg dose Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) , published in New England Journal of Medicine (Jastreboff AM et al., 2022; PMID: 35658024): The study showed mean weight reduction of 15.0% , 19.5% , 20.9% vs 3.1% placebo at 72 weeks The study showed up to 36% of pa
dosing · pending
rticipants achieved 25% or more weight loss with tirzepatide 15 mg Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2) , published in The Lancet (Garvey WT et al., 2023; PMID: 37385275): The study showed mean weight reduction of 12.8% and 14.7% vs 3.2% placebo at 72 weeks The study showed HbA1c reduction of 2.1% and 2.1% vs 0.5% placebo References # Related Reading # Tirzepatide research studies and evidence Tirzepatide dosing protocols Tirzepatide side effects profile Exenatide research guide Liraglutide research guide Footnotes # Jastreboff AM, Aronne LJ, Ahmad NN, et al.
dosing · pending
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).
safety · pending
Efficacy and Safety of the Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1).
dosing · pending
↩ Stay current on Tirzepatide research We summarize new studies, safety updates, and dosing insights — delivered biweekly.
safety · pending
he side effects of tirzepatide?
safety · pending
The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, and constipation.
dosing · pending
These are typically mild to moderate and occur most frequently during dose escalation.
safety · pending
Serious risks include a boxed warning for thyroid C-cell tumors found in rodent studies.
mechanism · pending
Tirzepatide is a dual GIP/GLP-1 receptor agonist while semaglutide targets only GLP-1 receptors.
dosing · pending
In the SURPASS-2 head-to-head trial, tirzepatide showed greater A1C reduction and weight loss than semaglutide 1 mg.
dosing · pending
In the SURMOUNT-1 Phase 3 trial, participants on the highest dose (15 mg) lost an average of 22.5% of body weight over 72 weeks.
dosing · pending
Weight Loss & Metabolism Anti-Obesity Retatrutide 28.7% body weight loss in Phase 3 TRIUMPH-4 at 68 weeks (Dec 2025) -- see dosing, side effects, FDA approval timeline.
regulatory · pending
Tirzepatide is FDA-approved and available today.
regulatory · pending
Tirzepatide is the established leader with 20.9% weight loss, FDA approval, and thousands of patients studied.
Processing
Processed into 16 searchable sections.